Compounds · Oral incretins · continued

Why oral semaglutide needs an absorption enhancer at all posts 61–66

Compounds › Oral incretins randomised trial orforglipron oral semaglutide SOUL trial Solved

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.

k.vanheckeTL224 Dec 2025#61

h.hutchings, post #26: Dose numbers for oral formulations are not comparable to injectable ones. The 14 mg oral dose is not equivalent to any injectable dose in the traditional comparison sense. They are different formulations with different pharmacokinetics and cannot be put on the same scale. Go to post

Missed doses behave differently for a daily oral than for a weekly injection. With a short interval you are near a trough rather than perturbing a slowly moving average, and the labelling reflects that.

7 likes in reply to #26 7mo

k.fonsecaTL227 Dec 2025#62

Collapsed as off-topic by two members at trust level 3 or above

On variability: the between-person spread in exposure for oral semaglutide is wide enough that two people on the same dose can have quite different plasma concentrations. That is inherent to the absorption route.

bench_notesTL4 Moderator30 Dec 2025#63

Why administration conditions matter for oral semaglutide and not for injectables: the oral formulation depends on a transient pH effect in the stomach. Anything that changes gastric pH or transit time changes absorption. Food does both.

The disagreement above is smaller than it looks once the terms are fixed.

0 likes 7mo

v.baptistaTL23 Jan 2026#64

f.haddad, post #41: PIONEER 6 is the cardiovascular outcome trial for oral semaglutide and it enrolled a diabetes population at high cardiovascular risk. Quoting it outside that population is an extrapolation. Go to post

Confirming post #61 from a second method, which matters more than confirming it from a second person.

SNAC is the sodium N-(8-[2-hydroxybenzoyl]amino) caprylate, an absorption enhancer that transiently raises local pH in the stomach and promotes gastric mucosal absorption. Without it, oral bioavailability of semaglutide would be too low for clinically useful dosing.

Nothing above should be read as advice about what anyone else should do.

24 likes in reply to #41 7mo

PharmNotes_WhitfieldTL4Pharmacist6 Jan 2026#65

Post #61 describes the usual case. This is about the unusual one.

Oral bioavailability is variable between people. Some people absorb well; others absorb poorly. That inter-individual variation is larger than with injectables and is one reason the trial data for oral formulations receives different treatment.

That is all I can say without guessing.

3 likes 7mo

a.vukovicTL29 Jan 2026#66

I read the earlier replies on oral semaglutide twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with what was said rather than what I expected.

0 likes 7mo

This topic was referenced in

Oral versus injectable exposure: comparing apples to a different fruitCompounds › Oral incretins · 23 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes Compounds › Oral incretins randomised trial SOUL trial oral semaglutide orforglipron Solved The SOUL trial and oral semaglutide cardiovascular outcomes — setting out what I have, and where I think it stops being reliable. SOUL trial and oral semaglutide — I have the observation and I do not trust my…	+100	104	4.2k	5mo
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — does this still hold? Compounds › Oral incretins orforglipron SOUL trial oral semaglutide PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Posting a…	+23	27	4.8k	22mo
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one Compounds › Oral incretins PIONEER programme SOUL trial randomised trial orforglipron Solved PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — setting out what I have, and where I think it stops being reliable. Posting a small dataset on PIONEER 6 cardiovascular…	+25	29	22k	1d
Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Compounds › Oral incretins randomised trial oral semaglutide SOUL trial PIONEER programme Posting this under the heading it deserves: Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Everything below is what sits behind that. Something about Oral versus…	+27	31	17k	25d
Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Compounds › Oral incretins PIONEER programme orforglipron randomised trial SOUL trial Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Writing it up because I had to work it out twice and would rather nobody else did. Posting a small dataset on…		2	17k	6h

Related topics — sharing the tags randomised trial, orforglipron, oral semaglutide

Topic	Participants	Replies	Views	Activity
Hepatic effects of glucagon receptor agonism: the mechanistic worry Compounds › Retatrutide TRIUMPH programme effect size preprint randomised trial Solved Posting this under the heading it deserves: Hepatic effects of glucagon receptor agonism: the mechanistic worry Everything below is what sits behind that. Something about hepatic effects of glucagon receptor…	+51	56	700	22mo
Oral semaglutide bioavailability and its variability between people — a second dataset Compounds › Oral incretins randomised trial PIONEER programme SOUL trial Closed Oral semaglutide bioavailability and its variability between people — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Oral semaglutide…	+141	154	47k	19mo
Composite endpoints and the component doing the work Evidence › Trials randomised trial surrogate endpoints open label discontinuation & dropout Solved Under review Composite endpoints and the component doing the work Writing it up because I had to work it out twice and would rather nobody else did. Collecting what is known about composite endpoints in one place, because…	+3	7	33k	13h
Second pass at: Retatrutide dose escalation in the published trials Compounds › Retatrutide retatrutide randomised trial preprint Under review Second pass at: Retatrutide dose escalation in the published trials — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on Retatrutide…	+115	125	30k	2y
Open-label extensions: what survives and what does not Evidence › Trials discontinuation & dropout randomised trial estimand Closed Posting this under the heading it deserves: Open-label extensions: what survives and what does not Everything below is what sits behind that. I have spent a fortnight trying to pin open-label extensions down…		4	22k	3mo